Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Journal article

BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim. METHODS: COIN was a randomised controlled trial in patients with previously untreated advanced colorectal cancer. Patients received either continuous oxaliplatin and fluoropyrimidine...

Expand abstract

Authors: Adams, R; Meade, A; Seymour, M; Wilson, R; Madi, A

• Publication status: Published
• Journal: Lancet. Oncology
• Volume: 12
• Issue: 7
• Pages: 642-653
• Publication date: 2011-07-01
• DOI: 10.1016/s1470-2045(11)70102-4
• EISSN: 1474-5488
• ISSN: 1470-2045
• Language: English
• Keywords: Disease Progression; Antineoplastic Agents; Follow-Up Studies; Aged; Disease-Free Survival; Time Factors; Fluorouracil; Middle Aged; Quality of Life; Colorectal Neoplasms; MRC COIN Trial Investigators; Neoplasm Staging; Male; Organoplatinum Compounds; Female; Humans; Antimetabolites, Antineoplastic; Drug Therapy, Combination